Dermatologist inspecting a patient's skin

Routine NHS use of skin cancer drug recommended

NICE has recommended the routine NHS use of a new skin cancer drug, as an option after surgery for some patients with melanoma.

Final draft guidance on the drug (called nivolumab) was issued by NICE on February 12, 2021 with an appeal period now open until February 26, 2021.

Nivolumab was available for the past two years within the Cancer Drugs Fund, recommended for use as an option for the adjuvant treatment of completely resected melanoma in adults with lymph node involvement or metastatic disease.

This allowed for patients to access the drug while data on its effectiveness was being collected, in order to address significant clinical uncertainty.

Under these terms, its use was permitted in set circumstances but more data was required to be gathered before it could be considered for routine commissioning. This meant until recently, NICE had been unable to recommend the use of nivolumab in draft guidance.

Even now it has the data required to make the recommendation, NICE made clear reference to the fact the data from the Cancer Drugs Fund and key clinical trial were still relatively immature and so it was uncertain what impact nivolumab would have on life of time people lived for or by how much it increased overall survival rates.

Following consultation, the committee was persuaded that some of its preferred assumptions for estimating long-term survival of people who had been treated with nivolumab had been too conservative.

New analyses presented by the drug’s manufacturer showed that the most likely estimates of cost-effectiveness were within the range NICE considers a cost-effective use of NHS resources.

In response, the committee at NICE has now recommended the routine use of nivolumab as an option after surgery for some people with melanoma, subject to the drug manufacturer providing it according to the commercial arrangement agreed with the NHS.

NHE Sept/Oct 21

NHE Sept/Oct 21

Improving care for long-term conditions

Join us in our September/October edition of National Health Executive, as we explore a range of topics impacting and improving the care that we can deliver to patients, the facilities within which we deliver them, and the opportunities in the digital space to accent and evolve our care capabilities


View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Festival: Digital Healthcare

The integration of new technology, such as using virtual outpatient appointments instead of face-to-face reviews of patients in the hospital. Adapting the ways in which our NHS workers serve people has been critical in continuing to provide high-quality treatment, a positive patient experience and preventing Covid-19 transmission during the pandemic. Our healthcare sector has the potential to transform the way we continue to provide essential services while also improving patient care. But how easy is the integration of these innovations into routine NHS practice?

On the 28th of October, at the NHE365 Virtual Hospitals & Technology Enabled Care online event, we will be discussing patient flow and experience, reducing waiting times, reducing the patient backlog and increasing technology adoption. Will you be attending? 

Finger on the Pulse

Ep 14. Health messaging is a science, Professor Craig Jackson

On Episode 14 of NHE's Finger on the Pulse podcast, we're joined by Professor Craig Jackson, Professor of Occupational Health Psychology
Birmingham City University to discuss the coronavirus pandemic, the health messaging around it and how those in power have missed a trick by overlooking the key role of psychology in informing the public of restrictions, measures and the ever-changing situation

More articles...

View all